Efficacy and perioperative safety of FLOT regimen in neoadjuvant chemotherapy for gastric adenocarcinoma
10.3760/cma.j.cn113855-20200607-00460
- VernacularTitle:FLOT方案在胃腺癌新辅助化疗中的效果及围手术期安全性评估
- Author:
Junli ZHANG
1
;
Xijie ZHANG
;
Ying LIU
;
Sen LI
;
Pengfei MA
;
Yanghui CAO
;
Chenyu LIU
;
Zhenyu LI
;
Yuzhou ZHAO
Author Information
1. 郑州大学附属肿瘤医院普外科 450000
- From:
Chinese Journal of General Surgery
2020;35(11):847-851
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy and perioperative safety of FLOT regimen in neoadjuvant chemotherapy for gastric adenocarcinoma.Methods:Data of 128 cases of neoadjuvant chemotherapy for gastric adenocarcinoma at the General Surgery Department of He′nan Cancer Hospital from Jan2018 to July 2019 were divided into FLOT group and SOX/XELOX group.Results:The disease control rate in the FLOT group was 81%, while that in the SOX/XELOX group was only 60% ( P=0.040). In terms of TRG classification and ypT staging, the proportion of TRG0 / 1 in the FLOT group was 49%, which was significantly higher than 21% in the SOX / XELOX group ( P=0.001). In the FLOT group, ypT 0-4 was 2, 10, 8, 17 and 6, respectively, while in the SOX/XELOX group, ypT 0-4 was 1, 9, 15, 26 and 34, respectively, ( P=0.022). In the FLOT group, ypTNM stages Ⅰ, Ⅱ, and Ⅲ were 11, 20, and 12, respectively, while in the SOX/XELOX group, ypTNM stages Ⅰ, Ⅱ, and Ⅲ were 12, 30, and 43, respectively ( P=0.040). Complications occurred in 10 patients (23%) in the FLOT group and 18 patients (21%) in the SOX/XELOX group ( P>0.05). Conclusions:FLOT neoadjuvant chemotherapy for advanced gastric adenocarcinoma does not increase the incidence of perioperative complications while effecting tumor regression and downstaging compared to SOX/XELOX regimen.
